Now:Suggest a Topic: Difference between revisions
No edit summary |
|||
| Line 8: | Line 8: | ||
==Potential Topics== | ==Potential Topics== | ||
;Post potential topics here, with link to EBQ page if currently present | |||
*Octreotide for upper GI bleed | *Octreotide for upper GI bleed | ||
*Metoprolol vs. diltiazem in for A. fib with RVR | *Metoprolol vs. diltiazem in for A. fib with RVR | ||
*Kayexelate for patients with hyperkalemia in renal failure | *[[EBQ:Use of Sodium Polystyrene Sulfonate (Kayexylate) in Hyperkalemia|Kayexelate for patients with hyperkalemia in renal failure]] | ||
*tPA use in acute CVA | *tPA use in acute CVA | ||
*tPA in PE subsets | *tPA in PE subsets | ||
Revision as of 02:30, 11 February 2015
Background
This is the page to suggest controversial emergency medicine issues for us to pilot on WikEM-Now. The ideal (at least initial) topics are ones in which:
- there is true debate in the literature
- there currently lacks a clear management guideline
- and, in which doctors have to actually make a decision in real life.
The evidence may be unclear, but that does not stop us from having to choose an option. Theoretical debates are not of interest.
Potential Topics
- Post potential topics here, with link to EBQ page if currently present
- Octreotide for upper GI bleed
- Metoprolol vs. diltiazem in for A. fib with RVR
- Kayexelate for patients with hyperkalemia in renal failure
- tPA use in acute CVA
- tPA in PE subsets
- Discharge of Newly Diagnosed Pulmonary Embolism From the ED
- CTA vs V/Q in pregnant pts needing PE r/o
- NEXUS vs. Canadian c-spine rules